Haemophilia specialist nurses’ perceptions of haemophilia B

1 Castaman G, Matino D. Hemophilia A and B: molecular and clinical similarities and differences. Haematologica 2019; 104: 1702–1709. doi: 10.3324/haematol.2019.221093. CastamanG MatinoD Hemophilia A and B: molecular and clinical similarities and differences Haematologica 2019 104 1702 1709 10.3324/haematol.2019.221093 671758231399527 Open DOISearch in Google Scholar

2 Melchiorre D, Linari S, Manetti M, et al. Clinical, instrumental, serological and histological findings suggest that hemophilia B may be less severe than hemophilia A. Haematologica 2016; 101: 219–25. doi: 10.3324/haematol.2015.133462. MelchiorreD LinariS ManettiM Clinical, instrumental, serological and histological findings suggest that hemophilia B may be less severe than hemophilia A Haematologica 2016 101 219 25 10.3324/haematol.2015.133462 493833026494839 Open DOISearch in Google Scholar

3 Kihlberg K, Baghaei F, Bruzelius M, et al. Treatment outcomes in persons with severe haemophilia B in the Nordic region: The B-NORD study. Haemophilia 2021; 27(3): 366–374. doi: 10.1111/hae.14299. KihlbergK BaghaeiF BruzeliusM Treatment outcomes in persons with severe haemophilia B in the Nordic region: The B-NORD study Haemophilia 2021 27 3 366 374 10.1111/hae.14299 33780113 Open DOISearch in Google Scholar

4 Shih MY, Wang JD, Yin JD, et al. Differences in major bleeding events between patients with severe hemophilia A and hemophilia B: a nationwide, population-based cohort study. Clin Appl Thromb Hemost 2019; 25: 1076029619888023. doi: 10.1177/1076029619888023. ShihMY WangJD YinJD Differences in major bleeding events between patients with severe hemophilia A and hemophilia B: a nationwide, population-based cohort study Clin Appl Thromb Hemost 2019 25 1076029619888023 10.1177/1076029619888023 709820731928075 Open DOISearch in Google Scholar

5 Dolan G, Benson G, Duffy A, et al. Haemophilia B: Where are we now and what does the future hold? Blood Rev 2018; 32(1): 52–60. doi: 10.1016/j.blre.2017.08.007. DolanG BensonG DuffyA Haemophilia B: Where are we now and what does the future hold? Blood Rev 2018 32 1 52 60 10.1016/j.blre.2017.08.007 28826659 Open DOISearch in Google Scholar

6 Clausen N, Petrini P, Claeyssens-Donadel S et al; PedNet and Research of Determinants of Inhibitor development (RODIN) Study Group. Similar bleeding phenotype in young children with haemophilia A or B: a cohort study. Haemophilia 2014; 20: 747–55. doi: 10.1111/hae.12470. ClausenN PetriniP Claeyssens-DonadelS PedNet and Research of Determinants of Inhibitor development (RODIN) Study Group Similar bleeding phenotype in young children with haemophilia A or B: a cohort study Haemophilia 2014 20 747 55 10.1111/hae.12470 24893572 Open DOISearch in Google Scholar

7 Osooli M, Steen Carlsson K, Astermark J, et al. Surgery and survival in birth cohorts with severe haemophilia and differences in access to replacement therapy: The Malmö experience. Haemophilia 2017; 23(5): e403–e408. doi: 10.1111/hae.13302. OsooliM Steen CarlssonK AstermarkJ Surgery and survival in birth cohorts with severe haemophilia and differences in access to replacement therapy: The Malmö experience Haemophilia 2017 23 5 e403 e408 10.1111/hae.13302 28758324 Open DOISearch in Google Scholar

8 Alprolix Summary of Product Characteristics. Available from https://www.ema.europa.eu/en/documents/product-information/alprolix-epar-product-information_en.pdf (accessed 27 August 2021). Alprolix Summary of Product Characteristics Available from https://www.ema.europa.eu/en/documents/product-information/alprolix-epar-product-information_en.pdf (accessed 27 August 2021). Search in Google Scholar

9 Idelvion Summary of Product Characteristics. Available from https://www.ema.europa.eu/en/documents/product-information/idelvion-epar-product-information_en.pdf (accessed 27 August 2021). Idelvion Summary of Product Characteristics Available from https://www.ema.europa.eu/en/documents/product-information/idelvion-epar-product-information_en.pdf (accessed 27 August 2021). Search in Google Scholar

10 Refixia Summary of Product Characteristics. Available from https://www.ema.europa.eu/en/documents/product-information/refixia-epar-product-information_en.pdf (accesed 27 August 2021). Refixia Summary of Product Characteristics Available from https://www.ema.europa.eu/en/documents/product-information/refixia-epar-product-information_en.pdf (accesed 27 August 2021). Search in Google Scholar

11 Iorio A, Fischer K, Blanchette V, Rangarajan S, Young G, Morfini M; Pharmacokinetic (PK) Expert Working Group of the International Prophylaxis Study Group (the IPSG). Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates. Thromb Haemost 2017; 117(6): 1023–1030. doi: 10.1160/TH16-12-0942. IorioA FischerK BlanchetteV RangarajanS YoungG MorfiniM Pharmacokinetic (PK) Expert Working Group of the International Prophylaxis Study Group (the IPSG) Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates Thromb Haemost 2017 117 6 1023 1030 10.1160/TH16-12-0942 28357444 Open DOISearch in Google Scholar

12 Negrier C, Knobe K, Tiede A, et al. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 2011; 118(10): 2695–701. doi: 10.1182/blood-2011-02-335596. NegrierC KnobeK TiedeA Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B Blood 2011 118 10 2695 701 10.1182/blood-2011-02-335596 21555744 Open DOISearch in Google Scholar

13 Santagostino E, Negrier C, Klamroth R, et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012; 120(12): 2405–11. doi: 10.1182/blood-2012-05-429688. SantagostinoE NegrierC KlamrothR Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients Blood 2012 120 12 2405 11 10.1182/blood-2012-05-429688 344825522859609 Open DOISearch in Google Scholar

14 Machin N, Ragni MV. An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B. J Blood Med 2018; 9: 135–140. doi: 10.2147/JBM.S159297. MachinN RagniMV An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B J Blood Med 2018 9 135 140 10.2147/JBM.S159297 Open DOISearch in Google Scholar

15 Shapiro AD. Concizumab: a novel anti-TFPI therapeutic for hemophilia. Blood Adv 2021; 5(1): 279. doi: 10.1182/bloodadvances.2019001140. ShapiroAD Concizumab: a novel anti-TFPI therapeutic for hemophilia Blood Adv 2021 5 1 279 10.1182/bloodadvances.2019001140 Open DOISearch in Google Scholar

16 Kahneman D, Tversky A. Judgement under uncertainty: heuristics and biases. Science 1974; 185: 1124–1131. doi: 10.1126/science.185.4157.1124. KahnemanD TverskyA Judgement under uncertainty: heuristics and biases Science 1974 185 1124 1131 10.1126/science.185.4157.1124 Open DOISearch in Google Scholar

17 Tversky A, Kahneman D. Availability: A heuristic for judging frequency and probability. Cognitive Psychology 1973; 5: 207–232. doi: 10.1016/0010-0285(73)90033-9. TverskyA KahnemanD Availability: A heuristic for judging frequency and probability Cognitive Psychology 1973 5 207 232 10.1016/0010-0285(73)90033-9 Open DOISearch in Google Scholar

18 Srivastava A, Santagostino E, Dougall A, et al.; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020; 26 Suppl 6: 1–158. doi: 10.1111/hae.14046. SrivastavaA SantagostinoE DougallA WFH Guidelines for the Management of Hemophilia panelists and co-authors WFH Guidelines for the Management of Hemophilia, 3rd edition Haemophilia 2020 26 Suppl 6 1 158 10.1111/hae.14046 32744769 Open DOISearch in Google Scholar

19 Mansouritorghabeh H, Mohades ST. Is the detection of factor IX inhibitors in hemophilia B orphan than factor VIII inhibitors in hemophilia A? A concise, systematic review. Cardiovasc Hematol Disord Drug Targets 2020; 20(3): 185–190. doi: 10.2174/1871529X20666200701104143. MansouritorghabehH MohadesST Is the detection of factor IX inhibitors in hemophilia B orphan than factor VIII inhibitors in hemophilia A? A concise, systematic review Cardiovasc Hematol Disord Drug Targets 2020 20 3 185 190 10.2174/1871529X20666200701104143 32611303 Open DOISearch in Google Scholar

20 Rendo P, Smith L, Lee HY, et al. Nonacog alfa: an analysis of safety data from six prospective clinical studies in different patient populations with haemophilia B treated with different therapeutic modalities. Blood Coagul Fibrinolysis 2015; 26(8): 912–8. doi: 10.1097/MBC.0000000000000359. RendoP SmithL LeeHY Nonacog alfa: an analysis of safety data from six prospective clinical studies in different patient populations with haemophilia B treated with different therapeutic modalities Blood Coagul Fibrinolysis 2015 26 8 912 8 10.1097/MBC.0000000000000359 26196195 Open DOISearch in Google Scholar

21 Mahlangu JN. Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B. Ther Adv Hematol 2018; 9(11): 335–346. doi: 10.1177/2040620718802606. MahlanguJN Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B Ther Adv Hematol 2018 9 11 335 346 10.1177/2040620718802606 619663130364483 Open DOISearch in Google Scholar

22 Pollard D, Harrison C, Dodgson S, et al. The UK haemophilia specialist nurse: Competencies fit for practice in the 21st century. Haemophilia 2020; 26(4): 622–630. doi: 10.1111/hae.14002. PollardD HarrisonC DodgsonS The UK haemophilia specialist nurse: Competencies fit for practice in the 21st century Haemophilia 2020 26 4 622 630 10.1111/hae.14002 749622632311205 Open DOISearch in Google Scholar

23 O'Mahony B, Noone D, Prihodova L. Survey of coagulation factor concentrates tender and procurement procedures in 38 European Countries. Haemophilia 2015; 21(4): 436–43. doi: 10.1111/hae.12720. O'MahonyB NooneD PrihodovaL Survey of coagulation factor concentrates tender and procurement procedures in 38 European Countries Haemophilia 2015 21 4 436 43 10.1111/hae.12720 25996253 Open DOISearch in Google Scholar

24 Hay CR. Purchasing factor concentrates in the 21st century through competitive tendering. Haemophilia 2013; 19(5): 660–7. doi: 10.1111/hae.12169. HayCR Purchasing factor concentrates in the 21st century through competitive tendering Haemophilia 2013 19 5 660 7 10.1111/hae.12169 23711201 Open DOISearch in Google Scholar

25 Garner K, Guelcher C, Pollard D. The use of rIX-FP in patients with haemophilia B: A nurse's perspective. J Haem Pract 2021; 8(1): 86–97. doi: 10.17225/jhp00180. GarnerK GuelcherC PollardD The use of rIX-FP in patients with haemophilia B: A nurse's perspective J Haem Pract 2021 8 1 86 97 10.17225/jhp00180 Open DOISearch in Google Scholar

26 Valentino LA, Blanchette V, Negrier C, et al. Personalising haemophilia management with shared decision making. J Haem Pract 2021; 8(1): 69–79. doi: 10.17225/jhp00178. ValentinoLA BlanchetteV NegrierC Personalising haemophilia management with shared decision making J Haem Pract 2021 8 1 69 79 10.17225/jhp00178 Open DOISearch in Google Scholar

27 Buckner TW, Sidonio R Jr, Witkop M, et al. Correlations between patient-reported outcomes and self-reported characteristics in adults with hemophilia B and caregivers of children with hemophilia B: analysis of the B-HERO-S study. Patient Relat Outcome Meas 2019; 10: 299–314. doi: 10.2147/PROM.S219166. BucknerTW SidonioRJr WitkopM Correlations between patient-reported outcomes and self-reported characteristics in adults with hemophilia B and caregivers of children with hemophilia B: analysis of the B-HERO-S study Patient Relat Outcome Meas 2019 10 299 314 10.2147/PROM.S219166 675524331572035 Open DOISearch in Google Scholar

28 Cutter S, Guelcher C, Hunter S, et al. Mild-severe hemophilia B impacts relationships of US adults and children with hemophilia B and their families: results from the B-HERO-S study. Patient Relat Outcome Meas 2019; 10: 257–266. doi: 10.2147/PROM.S214188. CutterS GuelcherC HunterS Mild-severe hemophilia B impacts relationships of US adults and children with hemophilia B and their families: results from the B-HERO-S study Patient Relat Outcome Meas 2019 10 257 266 10.2147/PROM.S214188 670162031496854 Open DOISearch in Google Scholar

29 Blamey G, Buranahirun C, Buzzi A, et al. Hemophilia and sexual health: results from the HERO and B-HERO-S studies. Patient Relat Outcome Meas 2019; 10: 243–255. doi: 10.2147/PROM.S211339. BlameyG BuranahirunC BuzziA Hemophilia and sexual health: results from the HERO and B-HERO-S studies Patient Relat Outcome Meas 2019 10 243 255 10.2147/PROM.S211339 669858831616195 Open DOISearch in Google Scholar

30 Buckner TW, Witkop M, Guelcher C, et al. Impact of hemophilia B on quality of life in affected men, women, and caregivers – Assessment of patient-reported outcomes in the B-HERO-S study. Eur J Haematol 2018; 100(6): 592–602. doi: 10.1111/ejh.13055. BucknerTW WitkopM GuelcherC Impact of hemophilia B on quality of life in affected men, women, and caregivers – Assessment of patient-reported outcomes in the B-HERO-S study Eur J Haematol 2018 100 6 592 602 10.1111/ejh.13055 29505680 Open DOISearch in Google Scholar

31 Benefix Summary of Product Characteristics. Available from https://www.ema.europa.eu/en/documents/product-information/benefix-epar-product-information_en.pdf (accessed 27 August 2021). Benefix Summary of Product Characteristics Available from https://www.ema.europa.eu/en/documents/product-information/benefix-epar-product-information_en.pdf (accessed 27 August 2021). Search in Google Scholar

32 Rixubis Summary of Product Characteristics. Available from https://www.ema.europa.eu/en/documents/product-information/rixubis-epar-product-information_en.pdf (accessed 27 August 2021). Rixubis Summary of Product Characteristics Available from https://www.ema.europa.eu/en/documents/product-information/rixubis-epar-product-information_en.pdf (accessed 27 August 2021). Search in Google Scholar